Trial Profile
A Phase II Study of Capecitabine, Oxaliplatin (XELOX) and Bevacizumab for patient with high-risk Upper Rectal Cancer as Neo-Adjuvant chemotherapy.
Status:
Discontinued
Phase of Trial:
Phase II
Latest Information Update: 03 Jun 2020
Price :
$35
*
At a glance
- Drugs Bevacizumab (Primary) ; Capecitabine (Primary) ; Oxaliplatin (Primary)
- Indications Adenocarcinoma; Rectal cancer
- Focus Therapeutic Use
- Acronyms COBURA
- 01 Jun 2020 Status changed from recruiting to discontinued.
- 03 Dec 2014 New trial record